Insulet Shares Plunge After Cutting 2026 Sales Forecast on Slower U.S. Omnipod Growth

Insulet lowered its full-year sales outlook, citing weaker U.S. Omnipod demand and lower retention among type 2 diabetes users. The news heightens scrutiny on peers in the insulin pump and CGM space.